This article is more than 5 years old. Information may no longer be current.
Higher chlorhexidine gluconate concentrations more effective for elimination of MRSA in PJI model
Click Here to Manage Email Alerts
Results from an in vitro periprosthetic joint infection model indicated higher concentrations of a chlorhexidine gluconate solution were better than lower concentrations to eliminate biofilm, with the greatest efficacy seen with concentrations of 2%.
Researchers incubated methicillin-resistant Staphylococcus aureus (MRSA) at 37° C overnight after suspension in a trypticase soy broth (TSB) liquid culture. Bacteria were treated with 3 mL of TSB, placed into titanium-alloy disks and put into six well-plates to grow biofilms. Biofilm was verified with gylcocalyx matrix development.
The investigators categorized the disks into six groups (A through F), with group A serving as the control of saline pulse irrigation and saline scrub. After irrigation, groups B through F were scrubbed for 1 minute with a 20 mL solution containing 4%, 2%, 1%, 0.5% and 0.25% of chlorhexidine gluconate (CG), respectively. Researchers conducted colony counts to evaluate colony forming units (CFUs) and evaluated bacteria growth using a second set of six plates that were reincubated in 3 mL TSB at 37° C.
Results showed group A had the most bacteria growth, and group C (with a 2% CG concentration) had the fewest CFUs. The next fewest CFUs were seen in groups D, E, B and F, respectively. In the reincubation group, results for the most and fewest CFUs still held. Investigators found significantly more CFUs in groups D and F compared with groups B and C, according to the study.
“The observed efficacy of 2% solution and the decrease in the bacteria kill rate transitioning from 2% to 1% make 2% the most advantageous concentration to balance antimicrobial effect with minimal potential side effects,” the authors wrote. ‒ by Monica Jaramillo
Disclosures: Smith reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts